Plasma endothelin-1 levels in liver cirrhosis

C M Bruno1, S Neri, C Sciacca

  • 1Department of Internal Medicine, University of Catania, Italy.

International Journal of Clinical & Laboratory Research
|April 6, 2001
PubMed

Insights

Plasma endothelin-1 levels are not elevated in all liver cirrhosis patients. Increased endothelin-1 is only detected in those with severe (Child C) hepatic failure, suggesting a role in advanced disease.

Area of Science:

  • Cardiology
  • Hepatology
  • Endocrinology

Background:

  • Circulating endothelin-1, a potent vasoconstrictor, is implicated in circulatory dysfunction in liver cirrhosis.
  • Previous studies reported increased plasma endothelin-1 in cirrhotic patients, but its role remains controversial.
  • The relationship between endothelin-1 levels and liver disease severity needs further clarification.

Purpose of the Study:

  • To investigate the correlation between liver disease severity, classified by Child's classification, and plasma endothelin-1 concentrations in cirrhotic patients.
  • To compare plasma endothelin-1 levels in cirrhotic patients with a healthy control group.

Main Methods:

  • Twenty-two cirrhotic patients and 10 healthy controls were enrolled after providing informed consent.
  • Patients were categorized according to Child's classification (A, B, or C).
  • Plasma endothelin-1 levels were quantified using a commercial radioimmunoassay kit.

Main Results:

  • Overall plasma endothelin-1 levels did not differ significantly between cirrhotic patients and healthy controls.
  • No significant differences were observed in Child A and B cirrhotic patients compared to controls.
  • A statistically significant increase in plasma endothelin-1 was found exclusively in Child C cirrhotic patients compared to Child A and B groups.

Conclusions:

  • Elevated circulating endothelin-1 is not a universal finding in all liver cirrhosis patients.
  • Higher plasma endothelin-1 levels are specifically associated with advanced hepatic failure (Child C classification).
  • The study suggests that increased endothelin-1 may be a consequence of hemodynamic changes in advanced cirrhosis or play a pathogenic role.

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Esophageal Varices-I: Introduction01:24

Esophageal Varices-I: Introduction

Esophageal varices are dilated, tortuous veins which are found mainly in the submucosa of the lower esophagus but which may also appear higher up or extend into the stomach. They develop due to increased pressure in the portal venous system, often as a result of liver cirrhosis. This condition scars and damages the liver, impeding normal blood flow through the portal vein. To compensate, blood seeks alternative pathways, forming fragile new vessels (varices) in the esophagus and stomach. These...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Portal Hypertension01:22

Portal Hypertension

Portal hypertension is an increase in blood pressure within the portal venous system. Normally, this pressure is less than 5 mmHg. It is considered clinically significant when it rises above 10 mmHg. At this threshold, complications from altered blood flow and venous congestion emerge.EtiologyPortal hypertension arises from conditions that impede blood flow through the liver. The most common cause is cirrhosis, in which chronic liver injury leads to fibrotic scarring. This fibrosis narrows or...
Ascites01:19

Ascites

DefinitionAscites is the buildup of fluid inside the peritoneal cavity. It occurs when fluid moves out of the vascular system faster than the peritoneal lymphatics can remove it. This fluid shift is most commonly seen in liver cirrhosis but can also appear in several other systemic disorders.EtiologyCirrhosis remains the leading cause of ascites. Other conditions that can contribute include:Heart failureConstrictive pericarditisAbdominal cancersNephrotic syndromeSevere protein–calorie...